15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Bio-Rad Laboratories Inc, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $290.00 to $320.00, so the covering firms are broadly aligned. The average target of $303.33 sits 8% below the current $331.44. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.31 next quarter toward $9.72 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Bio-Rad Laboratories Inc.
As of Jul, 1 of 3 firms rate BIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BIO EPS & revenue forecast
EPS · NEXT QUARTER
$2.31
Range $2.13 – $2.58 · 3 analysts · +2% YoY
Next period, 3 analysts expect Bio-Rad Laboratories Inc to earn $2.31 a share (range $2.13 – $2.58), versus $2.26 a year earlier. Full-year consensus is $9.00, growing to $9.72 the year after.
REVENUE · NEXT QUARTER
$651.2M
Range $641.9M – $658.0M · 3 analysts · -0% YoY
Revenue is expected to reach $651.2M (range $641.9M – $658.0M), -0.3% year-over-year. Full-year consensus is $2.6B, rising to $2.6B next year.
Top analysts covering Bio-Rad Laboratories Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIO.
#1
Patrick Donnelly
Citigroup · Rank #260
Hold
$300.00-9.5% to target
Overall win rate
32%
+ Follow
#2
Conor McNamara
RBC Capital · Rank #349
Buy
$409.00+23.4% to target
Overall win rate
25%
+ Follow
#3
Brandon Couillard
Wells Fargo
Hold
$290.00-12.5% to target
Coverage
—
+ Follow
#4
DL
Dan Leonard
RBC Capital
Buy
$320.00-3.5% to target
Coverage
—
+ Follow
#5
DL
Dan Leonard
UBS
Buy
$310.00-6.5% to target
Coverage
—
+ Follow
BIO stock forecast FAQ
What is BIO's average 12-month price target?+
The 3 analysts with a live target average $303.33 for Bio-Rad Laboratories Inc over the next 12 months, ranging from a $320.00 high to a $290.00 low.
Is BIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BIO?+
The Street-high target is $320.00 (RBC Capital), and the Street-low is $290.00 (Wells Fargo). The average of all 3 active targets is $303.33.
How many Wall Street analysts cover BIO?+
3 analysts have an active rating on Bio-Rad Laboratories Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering BIO?+
Among analysts who currently cover BIO, Patrick Donnelly of Citigroup has the strongest overall Quantellect track record (Rank #260). Their current call is Hold with a $300.00 target.
What is Bio-Rad Laboratories Inc's projected EPS for next quarter?+
The consensus estimate is $2.31 per share (range $2.13 – $2.58) across 3 analysts. Full-year EPS is projected at $9.00, rising to $9.72 the following year.
How much revenue is Bio-Rad Laboratories Inc expected to report next quarter?+
Consensus revenue is $651.2M (range $641.9M – $658.0M). Full-year revenue is projected at $2.6B, growing to $2.6B next year.
Have analysts been upgrading or downgrading BIO lately?+
As of Jul, 1 of 3 firms rate BIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
